세계의 흉막염 치료 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 진단별, 치료별, 투여 형태별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Pleurodynia Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Diagnosis, By Treatment, By Mode of Administration, By End-User, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,588,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 8,052,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,712,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

흉막염 치료 세계 시장 규모는 2024년 1억 4,355만 달러로 평가되었습니다. 2030년까지 예측 기간 동안 연평균 5.25%의 꾸준한 성장이 예상됩니다.

흉막염 치료 세계 시장은 진단 기술의 발전과 질병 증가로 인해 헬스케어 산업에서 빠르게 발전하고 있는 분야입니다. 일반적으로 '악마의 손아귀'라고 불리는 흉막염은 주로 엔테로바이러스, 특히 콕사키 바이러스에 의해 발생하는 바이러스 감염으로 급성 흉통과 근육통이 특징이며, 주로 소아 및 젊은 성인에 의해 발생합니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	1억 4,355만 달러
시장 규모 : 2030년	1억 9,559만 달러
CAGR : 2025-2030년	5.25%
급성장 부문	경구
최대 시장	북미

분자진단, 특히 중합효소연쇄반응(PCR)과 차세대염기서열분석(NGS)의 획기적인 발전으로 진단 정확도가 크게 향상되고 발견까지의 시간이 단축되면서 시장 성장을 견인하고 있습니다. 이러한 기술 혁신은 초기 단계의 식별을 강화하고, 적시에 개입할 수 있게 하여 궁극적으로 환자의 결과를 개선할 수 있습니다.

그러나 이 시장은 표적 항바이러스 치료제의 부족과 진단의 복잡성으로 인해 상당한 문제에 직면해 있습니다. 전문적인 치료법이 없기 때문에 대증요법에 의존할 수밖에 없어 치료의 발전 폭이 좁아지고 있습니다. 또한 흉막염의 임상 증상은 종종 심장병이나 호흡기 질환을 모방하는 경우가 많아 오진이 많아 치료가 지연되거나 부적절한 치료로 이어질 수 있습니다. 이러한 장애물에도 불구하고 세계 흉막 질환 시장은 유병률 증가와 진단 연구에 대한 지속적인 투자로 인해 지속적인 성장세를 보이고 있습니다. 치료 격차를 해소하고 진단 프로토콜을 개선하는 것은 시장의 잠재력을 극대화하고 환자 치료를 개선하는 데 있어 매우 중요합니다.

주요 시장 성장 촉진요인

의료 연구와 기술의 발전

주요 시장 이슈

인지도 저하와 오진

주요 시장 동향

진단 기술의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 흉막염 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 진단(혈액 검사, 배양 검사, X선 검사)
  • 치료(진통제, 면역글로불린)
  • 투여 방법(경구, 주사, 점적)
  • 최종사용자별(병원, 약국, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 흉막염 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 흉막염 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 흉막염 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 흉막염 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 흉막염 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제13장 세계의 흉막염 치료 시장 : SWOT 분석

제14장 경쟁 구도

• Bristol-Myers Squibb Co
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Sanofi SA
• Johnson & Johnson
• Merck & Co Inc.
• GlaxoSmithKline PLC
• Reckitt Benckiser PLC
• Bayer AG
• Novartis AG

제15장 전략적 제안

LSH

영문 목차

영문목차

Global Pleurodynia Treatment Market was valued at USD 143.55 Million in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2030. The Global Pleurodynia Treatment Market represents a rapidly evolving segment within the healthcare industry, driven by advancements in diagnostic technology and increasing disease prevalence. Pleurodynia, commonly referred to as "Devil's Grip," is a viral infection primarily caused by enteroviruses, notably Coxsackievirus, and is characterized by acute chest pain and myalgia, predominantly affecting children and young adults.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 143.55 Million
Market Size 2030	USD 195.59 Million
CAGR 2025-2030	5.25%
Fastest Growing Segment	Oral
Largest Market	North America

Market growth is underpinned by significant developments in molecular diagnostics, particularly Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), which have substantially improved diagnostic precision and reduced the time to detection. These innovations enhance early-stage identification and allow for timely intervention, ultimately improving patient outcomes.

However, the market faces considerable challenges, primarily due to the lack of targeted antiviral therapies and diagnostic complexities. The absence of specialized treatment options results in a reliance on symptomatic management, limiting the scope of therapeutic advancements. Furthermore, pleurodynia's clinical presentation often mimics cardiac and respiratory disorders, leading to frequent misdiagnosis and delayed or inappropriate treatment. Despite these hurdles, the global pleurodynia treatment market is positioned for sustained growth, fueled by rising incidence rates and continued investment in diagnostic research. Addressing treatment gaps and refining diagnostic protocols will be critical to unlocking the market's full potential and enhancing patient care.

Key Market Drivers

Advancements in Medical Research and Technology

In recent years, the healthcare industry has experienced an unprecedented surge in medical research and technological advancements. These innovations have played a pivotal role in driving the growth of the Global Pleurodynia Treatment Market. Cutting-edge diagnostic tools and therapeutic options have been developed, significantly enhancing the management of pleurodynia.

One notable advancement is the utilization of molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) tests. These tests have revolutionized the accuracy and speed of pleurodynia diagnosis. By detecting the viral RNA in patient samples, PCR tests provide rapid and precise results, enabling healthcare professionals to initiate treatment promptly. NGS has also emerged as a game-changer in pleurodynia diagnosis and research. This high-throughput sequencing technology allows for the comprehensive analysis of viral genomes, aiding in the understanding of pleurodynia strains and their genetic variations. Such insights are invaluable for the development of targeted treatments.

Key Market Challenges

Limited Awareness and Misdiagnosis

One of the primary challenges hindering the growth of the Global Pleurodynia Treatment Market is the limited awareness among the general population. Pleurodynia, often referred to as "Devil's Grip," is a relatively uncommon viral infection. Many individuals may not recognize its symptoms, which can mimic other, more common ailments. This lack of awareness results in delayed diagnosis and treatment, impacting market growth.

The symptoms of pleurodynia, including severe chest pain and muscle aches, overlap with those of other respiratory and musculoskeletal conditions. Healthcare professionals may misdiagnose pleurodynia as conditions like pneumonia or muscular strain, leading to inappropriate treatment. Accurate and timely diagnosis is crucial for the effective management of pleurodynia, and misdiagnosis can slow down market expansion.

Key Market Trends

Advancements in Diagnostic Technologies

One significant trend in the Global Pleurodynia Treatment Market is the rapid advancement of diagnostic technologies. Molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) and next-generation sequencing (NGS), have gained prominence. These techniques enable healthcare professionals to detect pleurodynia with higher accuracy and speed by identifying viral RNA in patient samples. The adoption of these cutting-edge diagnostic tools is improving the efficiency of pleurodynia diagnosis and facilitating early treatment initiation.

Another notable trend is the development of point-of-care testing for pleurodynia. Point-of-care tests provide rapid results at the patient's bedside or in outpatient settings. These tests are particularly beneficial in regions with limited access to advanced healthcare facilities. The availability of point-of-care tests is expected to enhance the early detection and management of pleurodynia.

Key Market Players

• Bristol-Myers Squibb Co
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Sanofi SA
• Johnson & Johnson
• Merck & Co Inc.
• GlaxoSmithKline PLC
• Reckitt Benckiser PLC
• Bayer AG
• Novartis AG

Report Scope:

In this report, the Global Pleurodynia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pleurodynia Treatment Market, By Diagnosis:

• Blood test
• Culture test
• X-ray

Pleurodynia Treatment Market, By Treatment:

• Analgesics or Painkillers
• Immunoglobulin

Pleurodynia Treatment Market, By Mode of Administration:

• Oral
• Injections or infusion

Pleurodynia Treatment Market, By End-User:

• Hospitals
• Pharmacy
• Others

Pleurodynia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pleurodynia Treatment Market.

Available Customizations:

Global Pleurodynia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Pleurodynia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (Blood test, Culture test, X-ray)
  • 5.2.2. By Treatment (Analgesics or Painkillers, Immunoglobulin)
  • 5.2.3. By Mode of Administration (Oral, Injections or infusion)
  • 5.2.4. By End-User (Hospitals, Pharmacy, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Pleurodynia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Treatment
  • 6.2.3. By Mode of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pleurodynia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Mode of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Pleurodynia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Mode of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Pleurodynia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Mode of Administration
      • 6.3.3.2.4. By End User

7. Europe Pleurodynia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Treatment
  • 7.2.3. By Mode of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pleurodynia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Mode of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Pleurodynia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Mode of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Pleurodynia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Mode of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. France Pleurodynia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Mode of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Pleurodynia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Mode of Administration
      • 7.3.5.2.4. By End User

8. Asia-Pacific Pleurodynia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Treatment
  • 8.2.3. By Mode of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pleurodynia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Mode of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Pleurodynia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Mode of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Pleurodynia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Mode of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Pleurodynia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Mode of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Pleurodynia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Mode of Administration
      • 8.3.5.2.4. By End User

9. South America Pleurodynia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Treatment
  • 9.2.3. By Mode of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pleurodynia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Mode of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Pleurodynia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Mode of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Pleurodynia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Mode of Administration
      • 9.3.3.2.4. By End User

10. Middle East and Africa Pleurodynia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis
  • 10.2.2. By Treatment
  • 10.2.3. By Mode of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pleurodynia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Mode of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Pleurodynia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Mode of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Pleurodynia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Mode of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pleurodynia Treatment Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Bristol-Myers Squibb Co
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. F. Hoffmann-La Roche Ltd
• 14.3. Pfizer Inc
• 14.4. Sanofi SA
• 14.5. Johnson & Johnson
• 14.6. Merck & Co Inc.
• 14.7. GlaxoSmithKline PLC
• 14.8. Reckitt Benckiser PLC
• 14.9. Bayer AG
• 14.10.Novartis AG

15. Strategic Recommendations

관련자료